Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2019

10.07.2019 | Gastrointestinal Oncology

Short- and Long-Term Outcomes of Patients Requiring Gastrectomy During Cytoreductive Surgery and Intraperitoneal Chemotherapy for Lower-Gastrointestinal Malignancies: A Propensity Score-Matched Analysis

verfasst von: Bhavneet Singh, MBBS, Oliver M. Fisher, MD, PhD, Gurkirat Singh, MBBS, Joshua Lansom, MBBS, Michael Bock, MBBS, Mathew Kozman, MBBS, MS, FRACS, Nayef Alzahrani, MBBS, SBGS, Winston Liauw, MBBS, MMEDSCI, MP&Pol, FRACP, David L. Morris, MBChB, FRCS, MD, PhD, FRACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study was designed to assess the short- and long-term outcomes of gastric resection in cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) for lower gastrointestinal (GI) malignancies.

Methods

Patients with adenocarcinoma and appendiceal mucinous neoplasms were included. Redo and incomplete cytoreductions were excluded. A total of 756 patients were identified. Of these, 65 underwent gastric resection, 11 underwent wedge, 43 distal, and 11 subtotal and total gastrectomy. Preoperative differences were assessed for and addressed with matching. Perioperative outcomes, overall survival (OS), and risk-free survival (RFS) were assessed in two analyses: first all gastric resections were included and the second excluded wedge resections. Subgroup analysis according to diagnosis subtype was conducted.

Results

Demographic analysis revealed that markers of tumor aggression and poor nutrition were prevalent in the gastrectomy group. The matched analysis for gastric resections revealed higher rates of reoperation (38% vs. 22%, p = 0.028). After excluding wedge resections, increased rates of reoperation (40% vs. 22%, 0.019), grade 3/4 morbidity (76% vs. 59%, p = 0.036), and hospital stay (34 vs. 27 days, p = 0.012) were observed. For the unmatched cohort, OS (103 vs. 69 months, p = 0.501) and RFS (17 vs. 18 months, p = 0.181) for patients with CC = 0 were insignificantly different. In comparison for CC > 0, OS (31 vs. 83 months, p < 0.001) and RFS (9 vs. 20 months, p < 0.001) were significantly reduced in gastric resection. For the matched cohort, after excluding wedges, gastrectomy did not significantly decrease OS. However, RFS was decreased (11 vs. 20 months, p = 0.016).

Conclusions

Despite high postoperative morbidity, when complete cytoreduction is achieved, the need for gastric resection is not associated with inferior long-term outcomes.
Literatur
1.
Zurück zum Zitat Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed
2.
Zurück zum Zitat Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009 20;27:6237–42.CrossRef Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009 20;27:6237–42.CrossRef
3.
Zurück zum Zitat Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta-analyses. Cancer. 2007;109:692–702.CrossRefPubMed Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta-analyses. Cancer. 2007;109:692–702.CrossRefPubMed
4.
Zurück zum Zitat Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62.CrossRefPubMed Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62.CrossRefPubMed
5.
Zurück zum Zitat Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.CrossRef Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.CrossRef
6.
Zurück zum Zitat Goéré D, Passot G, Gelli M, et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperth. 2017;33:520–7.CrossRef Goéré D, Passot G, Gelli M, et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperth. 2017;33:520–7.CrossRef
7.
Zurück zum Zitat Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.CrossRefPubMed Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.CrossRefPubMed
8.
Zurück zum Zitat Pelz J, Doerfer J, Decker M, et al. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis. 2007;22:941–7.CrossRefPubMed Pelz J, Doerfer J, Decker M, et al. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis. 2007;22:941–7.CrossRefPubMed
9.
Zurück zum Zitat Saxena A, Yan TD, Chua TC, et al. Critical assessment of risk factors for complications after cytoreductive surgery and peroperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17;1291–301.CrossRefPubMed Saxena A, Yan TD, Chua TC, et al. Critical assessment of risk factors for complications after cytoreductive surgery and peroperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17;1291–301.CrossRefPubMed
10.
Zurück zum Zitat Chua TC, Saxena A, Schellekens JF, et al. Morbidity and mortality outcome s of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251;101–6.CrossRefPubMed Chua TC, Saxena A, Schellekens JF, et al. Morbidity and mortality outcome s of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251;101–6.CrossRefPubMed
11.
Zurück zum Zitat Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Br J Surg. 2002;89:208–12.PubMed Sugarbaker PH. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Br J Surg. 2002;89:208–12.PubMed
12.
Zurück zum Zitat Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:2188–94.CrossRefPubMed Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:2188–94.CrossRefPubMed
13.
Zurück zum Zitat Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B. Advanced Pseudomyxoma peritonei requiring gastrectomy to achieve complete cytoreduction results in good long-term oncologic outcomes. Ann Surg Oncol. 2016;23:4316–21.CrossRefPubMed Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B. Advanced Pseudomyxoma peritonei requiring gastrectomy to achieve complete cytoreduction results in good long-term oncologic outcomes. Ann Surg Oncol. 2016;23:4316–21.CrossRefPubMed
14.
Zurück zum Zitat Paredes AZ, Guzman-Pruneda FA, Abdel-Misih S, et al. Perioperative morbidity of gastrectomy during CRS-HIPEC: an ACS-NSQIP analysis. J Surg Res. 2019;241:31–9.CrossRefPubMed Paredes AZ, Guzman-Pruneda FA, Abdel-Misih S, et al. Perioperative morbidity of gastrectomy during CRS-HIPEC: an ACS-NSQIP analysis. J Surg Res. 2019;241:31–9.CrossRefPubMed
15.
Zurück zum Zitat Chua TC, Liauw W, Zhao J, et al. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2013;18:439–46.CrossRefPubMed Chua TC, Liauw W, Zhao J, et al. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2013;18:439–46.CrossRefPubMed
16.
Zurück zum Zitat Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.CrossRefPubMed Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.CrossRefPubMed
17.
Zurück zum Zitat Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373:189–96.CrossRefPubMed Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373:189–96.CrossRefPubMed
18.
Zurück zum Zitat Dindo D, Demartines N, Clavein PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;204;240;205–13.CrossRef Dindo D, Demartines N, Clavein PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;204;240;205–13.CrossRef
20.
Zurück zum Zitat Kozman MA, Fisher OM, Rebolledo BJ, et al. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. Eur J Surg Oncol. 2017;43:2299–307.CrossRefPubMed Kozman MA, Fisher OM, Rebolledo BJ, et al. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. Eur J Surg Oncol. 2017;43:2299–307.CrossRefPubMed
21.
Zurück zum Zitat Kozman MA, Fisher OM, Rebolledo BJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117:725–36.CrossRefPubMed Kozman MA, Fisher OM, Rebolledo BJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117:725–36.CrossRefPubMed
22.
Zurück zum Zitat Huo YR, Huang Y, Liauw W, et al. Prognostic value of carcinoembryonic antigen (CEA), AFP, CA19-9 and CA125 for patients with colorectal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Anticancer Res. 2016;36:1041–9.PubMed Huo YR, Huang Y, Liauw W, et al. Prognostic value of carcinoembryonic antigen (CEA), AFP, CA19-9 and CA125 for patients with colorectal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Anticancer Res. 2016;36:1041–9.PubMed
23.
Zurück zum Zitat Taflampas P, Dayal S, Chandrakumaran K, et al. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma peritonei: analysis of 519 patients. Eur J Surg Oncol. 2014;40:515–20.CrossRefPubMed Taflampas P, Dayal S, Chandrakumaran K, et al. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma peritonei: analysis of 519 patients. Eur J Surg Oncol. 2014;40:515–20.CrossRefPubMed
24.
Zurück zum Zitat Katz MH. Evaluating clinical and public health interventions: a practical guide to study design and statistics. London: Cambridge University Press; 2010.CrossRef Katz MH. Evaluating clinical and public health interventions: a practical guide to study design and statistics. London: Cambridge University Press; 2010.CrossRef
Metadaten
Titel
Short- and Long-Term Outcomes of Patients Requiring Gastrectomy During Cytoreductive Surgery and Intraperitoneal Chemotherapy for Lower-Gastrointestinal Malignancies: A Propensity Score-Matched Analysis
verfasst von
Bhavneet Singh, MBBS
Oliver M. Fisher, MD, PhD
Gurkirat Singh, MBBS
Joshua Lansom, MBBS
Michael Bock, MBBS
Mathew Kozman, MBBS, MS, FRACS
Nayef Alzahrani, MBBS, SBGS
Winston Liauw, MBBS, MMEDSCI, MP&Pol, FRACP
David L. Morris, MBChB, FRCS, MD, PhD, FRACS
Publikationsdatum
10.07.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07510-9

Weitere Artikel der Ausgabe 11/2019

Annals of Surgical Oncology 11/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.